117 related articles for article (PubMed ID: 15770965)
1. [Biological markers for diagnosis of Alzheimer's disease].
Takeda M; Tanaka T; Kudo T; Okochi M; Kamino A; Tagami S
Seishin Shinkeigaku Zasshi; 2004; 106(12):1610-4. PubMed ID: 15770965
[No Abstract] [Full Text] [Related]
2. [Neurochemical early and differential diagnostics for Alzheimer's disease].
Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
[TBL] [Abstract][Full Text] [Related]
3. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
4. [The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].
Shoji M
Rinsho Shinkeigaku; 2000 Dec; 40(12):1234-6. PubMed ID: 11464465
[TBL] [Abstract][Full Text] [Related]
5. [Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease].
Smach MA; Charfeddine B; Lammouchi T; Dridi H; Ben Othman L; Bennamou S; Limem K
Ann Biol Clin (Paris); 2008; 66(5):531-5. PubMed ID: 18957342
[TBL] [Abstract][Full Text] [Related]
6. New tests for Alzheimer's disease.
Health News; 2006 Jun; 12(6):2. PubMed ID: 16826618
[No Abstract] [Full Text] [Related]
7. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
9. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Kester MI; Verwey NA; van Elk EJ; Scheltens P; Blankenstein MA
Neurobiol Aging; 2010 Apr; 31(4):539-40; author reply 541. PubMed ID: 18963255
[No Abstract] [Full Text] [Related]
13. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
14. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
[TBL] [Abstract][Full Text] [Related]
15. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
16. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
17. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
18. [Biological marker for Alzheimer's disease].
Matsubara E
Brain Nerve; 2010 Jul; 62(7):769-75. PubMed ID: 20675881
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
20. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I
Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
